Get the Stockscreener App
0.7298
4.38%
-0.0302
Calcimedica Inc stock is traded at $0.7298, with a volume of 6,534.
It is down -4.38% in the last 24 hours and down -10.94% over the past month.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.
See More
Previous Close:
$0.7599
Open:
$0.736
24h Volume:
6,534
Relative Volume:
0.01
Market Cap:
$11.48M
Revenue:
-
Net Income/Loss:
$-19.54M
P/E Ratio:
-0.5583
EPS:
-1.3071
Net Cash Flow:
$-21.18M
1W Performance:
+3.14%
1M Performance:
-10.94%
6M Performance:
-85.81%
1Y Performance:
-80.88%
1-Day Range:
$0.6974
$0.7492
1-Week Range:
$0.6761
$0.7999
52-Week Range:
$0.4606
$7.20
Calcimedica Inc Stock (CALC) Company Profile
Name
Calcimedica Inc
Sector
Industry
Phone
858-952-5500
Address
505 COAST BOULEVARD SOUTH, LA JOLLA
Compare CALC vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CALC
Calcimedica Inc
|
0.7266 | 12.00M | 0 | -19.54M | -21.18M | -1.3071 |
VRTX
Vertex Pharmaceuticals Inc
|
485.40 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
674.35 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
907.15 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.37 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
283.43 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Calcimedica Inc Stock (CALC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-29-26 | Downgrade | H.C. Wainwright | Buy → Neutral |
Calcimedica Inc Stock (CALC) Latest News
CalciMedica Inc (CALC) Cash Flow - TradingKey
CalciMedica Inc (CALC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
CalciMedica Inc (CALC) Valuation: PE, PB & Fair Value Analysis - TradingKey
CalciMedica, Inc. Revenue Breakdown – NASDAQ:CALC - TradingView
TradingKey - TradingKey
CalciMedica Inc (CALC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
CALC|CalciMedica Inc|Price:0.760|Chg%:+0.044 - TradingKey
CalcimedicaProspectus Covers Resale Of Up To 56,020,287 Shares Of Common StockSEC Filing - TradingView
CalciMedica (NASDAQ: CALC) files to register 56M shares from June 2026 PIPE - Stock Titan
Form DEF 14A ATAI Beckley Inc For: 23 July By Investing.com - Investing.com Canada
CalciMedica, Inc. SEC Filing (Jul 23, 2026) - Stock Titan
CalciMedica (NASDAQ: CALC) plans reverse split, 7.5M-share equity plan boost and warrant votes - Stock Titan
Price to earnings forward of CalciMedica, Inc. – NASDAQ:CALC - TradingView
Enterprise value to revenue forward of CalciMedica, Inc. – NASDAQ:CALC - TradingView
CalciMedica (CALC): CVI Investments and Heights Capital disclose 5.1% equity stake - Stock Titan
Enterprise value to EBITDA forward of CalciMedica, Inc. – NASDAQ:CALC - TradingView
CalciMedica (CALC) price target decreased by 24.39% to 10.54 - MSN
Form PRE 14A ATAI Beckley Inc For: 13 July By Investing.com - Investing.com Australia
CalciMedica (NASDAQ: CALC) plans reverse split and warrant votes - Stock Titan
CalciMedica Stock Short Interest Rises to 33.91% - Moomoo
CALC News | CALCIMEDICA INC (NASDAQ:CALC) - ChartMill
[Form 3] CalciMedica, Inc. Initial Statement of Beneficial Ownership - Stock Titan
Alafi Capital Discloses Investment at CalciMedica with 17.1% Stake - TradingView
CalciMedica (CALC) gains 17.1% shareholder as Alafi Capital ups stake in $2.8M deal - Stock Titan
calcimedica inc glp-1 receptor agonists weight management diabetes treatments GLP-1 Receptor Agonists: antidiabetic and weight loss management drugs: A Complete Review - news36live
CalciMedica, Inc. Files Form 8-K with SEC: Key Company and Stock Information for July 2026 - Minichart
CALC Q1 2026 Earnings: Surprise Positive EPS Amidst Revenue AbsenceBook Value Growth - dars.gov.et
Form 4 CalciMedica Inc For: 7 July By Investing.com - Investing.com Nigeria
Director at CalciMedica (CALC) granted stock options on 20,000 shares - Stock Titan
CalciMedica (NASDAQ: CALC) director lists 2.1M shares and capped warrant holdings - Stock Titan
CalciMedica Announces Board Expansion and Leadership Transition - TipRanks
CalciMedica (NASDAQ: CALC) appoints Dr. Evgeny Zaytsev to board - Stock Titan
CalciMedica, Inc. Announces Board Changes, Effective July 2, 2026 - marketscreener.com
CALC Q1 2026 Earnings: Positive EPS Surprise Defies Expectations Amid Pre‑Revenue StatusPost-Earnings Reaction - dars.gov.et
CALCCalciMedica Inc Options - Finviz
CALC Should I Buy - Intellectia AI
CalciMedica (NASDAQ: CALC) gains 6.9% holder via June 2026 private placement - Stock Titan
Bering Partners II Discloses Investment at CalciMedica with 6.9% Stake - TradingView
Form 13D/A CALCIMEDICA For: 30 June By Investing.com - Investing.com Nigeria
CalciMedica (CALC) insiders add shares via open-market and unit purchases - Stock Titan
CALC Q1 2026 Earnings: EPS Surprise Beats Estimates by a Wide Margin; Stock DeclinesTech Earnings Analysis - dars.gov.et
Form 4 CalciMedica Inc For: 29 June By Investing.com - Investing.com South Africa
Calcimedica director Fred Middleton acquires $199,999 in stock. - Investing.com
Calcimedica director Fred Middleton acquires $199,999 in stock. By Investing.com - Investing.com Australia
CalciMedica (CALC) chief business officer gets 186,729-share stock award at $0.8033 - Stock Titan
CalciMedica (CALC) insider-affiliated fund buys 248,972 new shares at $0.8033 - Stock Titan
FDA raises no concerns over Auxora safety data, CalciMedica advances trial - MSN
CalciMedica (NASDAQ: CALC) lenders capped at 4.99% ownership after loan amendment - Stock Titan
Key facts: CalciMedica $15M raise; Auxora paused, FDA feedback due Q3 - TradingView
CalciMedica Receives FDA Clearance to Resume Auxora Clinical Trial for Acute Kidney Injury After Safety Review - Minichart
Calcimedica Inc Stock (CALC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.58%
1.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):